

## **EMERGERS PUBLISHES UPDATED ANALYSIS ABOUT PROLIGHT DIAGNOSTICS**

Emergers publishes updated analysis about Prolight Diagnostics with the title: "Gearing up for commercialisation with strong insider backing".

Among others, the article describes "Strong insider commitment signals confidence" and that Prolight is "Well-positioned for strategic partnering in 2025"

Read the article here: <https://www.emergers.se/prolight-j25/>

**For further information, please contact:**

Ulf Bladin, CEO

E-mail: [info@prolightdx.com](mailto:info@prolightdx.com)

Phone: +46 73 582 39 87

Company website: [www.prolightdx.com](http://www.prolightdx.com)

**About Us**

Prolight Diagnostics AB develops innovative Point-of-Care (POC) systems. These are small, portable instruments and disposable cartridges for performing in-vitro diagnostic (IVD) tests from a drop of blood.

We want to offer the foremost POC systems on the market for quick, reliable diagnosis of acute events. Our launch product will be for the measurement of troponin, to aid in the rule-in and rule-out of myocardial infarction.

The company's share is traded on the NGM Nordic SME marketplace, under the ticker PRLD.

**Attachments**

**Emergers publishes updated analysis about Prolight Diagnostics**